TNNI3K anticorps (Biotin)

N° du produit ABIN1402831

Détail du produit anti-TNNI3K anticorps (Biotin)

Antigène: TNNI3K (TNNI3 Interacting Kinase (TNNI3K))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TNNI3K est conjugé à/à la Biotin

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human TNNI3K

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur TNNI3K

Antigène: TNNI3K (TNNI3 Interacting Kinase (TNNI3K))

Autre désignation: TNNI3K (TNNI3K Produits)

Synonymes: anticorps CARK, anticorps Cark, anticorps D830019J24Rik, anticorps TNNI3 interacting kinase, anticorps serine/threonine-protein kinase TNNI3K, anticorps TNNI3K, anticorps LOC100592286, anticorps Tnni3k

Sujet:

Synonyms: Cardiac ankyrin repeat kinase, CARK, MGC142099, MGC33828, Serine/threonine protein kinase TNN13K, Serine/threonine-protein kinase TNNI3K, TNI3K_HUMAN, TNNI3 interacting kinase, TNNI3-interacting kinase, Tnni3k.

Background: TNNI3K, also known as CARK, is a 936 amino acid serine/threonine-protein kinase that is highly expressed in heart. Overexpression of TNNI3K leads to improved cardiac function by enhancing beating frequency and increasing contractile force and epinephrine response. TNNI3K suppresses phosphorylation of cardiac troponin I and p38/JNK-mediated apoptosis, therefore protecting the myocardium from ischemic injury. Administration of TNNI3K to mice with myocardial infarction improves cardiac performance and attentuates ventricular remodeling, suggesting that TNNI3K could be a promising target in the treatment of cardiac diseases. There are four isoforms of TNNI3K that are produced as a result of alternative splicing events.

ID gène: 51086